PUBLICATION

Global Business Reports

AUTHORS

Lina Jafari, Julian Issa, Margarita Todorova, Lorena Stancu

India Pharmaceuticals 2019

November 05, 2019

Known chiefly for its leadership in the generics space, India’s vast pharmaceutical market is one of the largest in the world by both volume, for which it is ranked third, and value, where it comes in at tenth. As the supplier of around 40% of generic demand in the United States and over 50% of global demand for various vaccines, the country has been aptly dubbed “the pharmacy of the world” for its critical role in supplying life saving medications to both developed and developing nations at affordable prices. While its prowess as an international pharmaceutical hub is hardly in question, India will face significant challenges in the years to come as the global industry modernizes and the renaissance in biopharmaceuticals and innovative therapies continue to alter the life sciences. As the 2020 milestone approaches, the question must be asked: how far has India come in achieving its government-led Pharma 2020 Vision to address these challenges? GBR sets out to answer this question in our latest IE publication, and following months of on-the-ground research, our field team encountered conflicting narratives across India’s three key pharmaceutical clusters: Mumbai, Hyderabad and Gujarat. 

RELATED INTERVIEWS MORE INTERVIEWS

Established in the year 2002, Surya Life Sciences is a manufacturer, exporter, and supplier of a wide assortment of bulk drug intermediates and fine API chemicals.
Bharat Parenterals is a research driven pharmaceutical company with a dedicated facility for antiretroviral drugs as well as a facility for general and B-lactam group of drugs.
DEFI Healthcare is an Ahmedabad-based pharmaceutical company involved in the manufacturing and supply of a wide range of avant-garde pharmaceuticals to semi-regulated and non-regulated markets across the globe.
GVK BIO is a global Contract Research & Development Organization providing drug discovery and development services to the biopharma industry and experiencing rapid growth.

MACIG

GBR speaks to Leopold Mboli Fatran, Minister of Mines and Geology of Central African Republic concerning the challenges of developing the country’s resource industries.

SUBSCRIBE TO OUR NEWSLETTER